pros and cons of glp 1 agonists TrimRX 2026 Employee Benefits Trends: Should

Discover how GLP-1 and GLP-1/GIP therapies (semaglutide and tirzepatide) influence body composition

We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

Learn about eligibility, deadlines, and how to file a claim.

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence